These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19104009)

  • 1. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus.
    Renzoni A; Kelley WL; Barras C; Monod A; Huggler E; François P; Schrenzel J; Studer R; Vaudaux P; Lew DP
    Antimicrob Agents Chemother; 2009 Mar; 53(3):903-11. PubMed ID: 19104009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus.
    Vaudaux P; Francois P; Berger-Bächi B; Lew DP
    J Antimicrob Chemother; 2001 Feb; 47(2):163-70. PubMed ID: 11157900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.
    Cui L; Lian JQ; Neoh HM; Reyes E; Hiramatsu K
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3404-13. PubMed ID: 16048954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.
    Renzoni A; Francois P; Li D; Kelley WL; Lew DP; Vaudaux P; Schrenzel J
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2958-65. PubMed ID: 15273106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.
    Maki H; McCallum N; Bischoff M; Wada A; Berger-Bächi B
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1953-9. PubMed ID: 15155184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin.
    Rybak MJ; Cha R; Cheung CM; Meka VG; Kaatz GW
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):119-25. PubMed ID: 15698717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus.
    Renzoni A; Andrey DO; Jousselin A; Barras C; Monod A; Vaudaux P; Lew D; Kelley WL
    PLoS One; 2011; 6(6):e21577. PubMed ID: 21738716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific mutation of Staphylococcus aureus VraS reveals a crucial role for the VraR-VraS sensor in the emergence of glycopeptide resistance.
    Galbusera E; Renzoni A; Andrey DO; Monod A; Barras C; Tortora P; Polissi A; Kelley WL
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1008-20. PubMed ID: 21173175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycopeptide resistance in coagulase-negative staphylococci.
    Biavasco F; Vignaroli C; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 2000 Jun; 19(6):403-17. PubMed ID: 10947214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.
    Cui L; Ma X; Sato K; Okuma K; Tenover FC; Mamizuka EM; Gemmell CG; Kim MN; Ploy MC; El-Solh N; Ferraz V; Hiramatsu K
    J Clin Microbiol; 2003 Jan; 41(1):5-14. PubMed ID: 12517819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
    Brown DF; Courvalin P
    Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance.
    McCallum N; Karauzum H; Getzmann R; Bischoff M; Majcherczyk P; Berger-Bächi B; Landmann R
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2352-60. PubMed ID: 16801412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
    Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals.
    Reverdy ME; Jarraud S; Bobin-Dubreux S; Burel E; Girardo P; Lina G; Vandenesch F; Etienne J
    Clin Microbiol Infect; 2001 May; 7(5):267-72. PubMed ID: 11422254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of mutation in the region (nt. 710-1010) of pbp4 gene in clinical isolates of Staphylococcus aureus with low-level teicoplanin resistance.
    Park Y; Oh EJ; Lee SO; Kim BK
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):271-3. PubMed ID: 11404074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR.
    Kato Y; Suzuki T; Ida T; Maebashi K
    J Antimicrob Chemother; 2010 Jan; 65(1):37-45. PubMed ID: 19889788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.